



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Klaus Fuchs et al) Art Unit: 1654
U.S. Appln. No. : 10/840,037) Examiner: T. S. Heard
Confirmation No. : 7763
U.S. Filing Date : May 6, 2004
Title of Invention : Novel Statine Derivatives For The Treatment of Alzheimer's Disease
Attny. Docket No.: 1/1497

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE


Sir:

This is in response to a communication from the Examiner, which communication was mailed on May 17, 2005. The communication mailed May 17th comprises a restriction requirement. The Examiner wishes to restrict the claims to either compound claims drawn to a SFT-1 based analog of Formula 1 (claims 1-14) or to a method of treating Alzheimer's disease (claims 15-18).

Applicants, through their attorney, hereby elect claims 1 through 14. As a single species, applicants elect compound number 14 of Table 1, on page 35 of the specification as filed.

Such election is without traverse.

Respectfully submitted,



Mary-Ellen M. Devlin
Attorney for Applicant(s)
Reg. No. 27,928

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4866
June 8, 2005

I hereby certify that this correspondence is
being deposited with the U.S. Postal Service
as first class mail in an envelope addressed
to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on June 8, 2005



By: Mary-Ellen M. Devlin
Reg. No. 27,928